Panacea Biotec Limited
Bombay Stock ExchangeTotal Valuation
Panacea Biotec Limited carries a market capitalization of 32.86B, placing it among publicly traded companies globally. Its enterprise value stands at 17.26B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 32.86B |
| Enterprise Value | 17.26B |
Share Statistics
Panacea Biotec Limited currently has 61.25M shares outstanding.
| Shares Outstanding | 61.25M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Panacea Biotec Limited trades at a trailing price-to-earnings ratio of 228.09. The price-to-sales ratio is 2.88, and the price-to-book ratio stands at 300.64.
| PE Ratio | 228.09 |
| PS Ratio | 2.88 |
| PB Ratio | 300.64 |
| P/TBV Ratio | 2.37 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 2.70 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 293.65 |
Financial Position
Panacea Biotec Limited maintains a current ratio of 1.47, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.85, indicating elevated leverage, while an interest coverage ratio of -6.23 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.47 |
| Quick Ratio | 0.39 |
| Debt / Equity | 2.85 |
| Debt / EBITDA | -0.63 |
| Interest Coverage | -6.23 |
Financial Efficiency
| Return on Equity (ROE) | -1.36 |
| Return on Assets (ROA) | -0.42 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.38 |
Taxes
Over the trailing twelve months, Panacea Biotec Limited has paid -2.10M in income taxes, reflecting an effective tax rate of 79.70.
| Income Tax | -2.10M |
| Effective Tax Rate | 79.70 |
Stock Price Statistics
Panacea Biotec Limited's stock has gained approximately 31.79525% over the past 52 weeks. The 50-day moving average sits at 463.25, while the 200-day moving average is 395.32.
| Beta (5Y) | N/A |
| 52-Week Price Change | 31.79525% |
| 50-Day Moving Average | 463.25 |
| 200-Day Moving Average | 395.32 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Panacea Biotec Limited generated 6.40B in revenue and converted that into -53.70M in net income, yielding earnings per share of -1.15. EBITDA reached -377.20M, while operating income came in at -377.20M.
| Revenue | 6.40B |
| Gross Profit | 3.59B |
| Operating Income | -377.20M |
| Pretax Income | -73.70M |
| Net Income | -53.70M |
| EBITDA | -377.20M |
| EBIT | -377.20M |
| Earnings Per Share (EPS) | -1.15 |
Balance Sheet
Panacea Biotec Limited holds 1.35B in cash and equivalents against 236.60M in total debt, resulting in a net debt position of -336.50M. Total book value stands at 61.30M, with working capital of 1.64B providing operational flexibility.
| Cash & Cash Equivalents | 1.35B |
| Total Debt | 236.60M |
| Net Debt | -336.50M |
| Equity (Book Value) | 61.30M |
| Book Value Per Share | 0.99 |
| Working Capital | 1.64B |
Margins
Panacea Biotec Limited operates with a gross margin of 56.16, reflecting its pricing power and cost economics. The operating margin of -5.90 and net profit margin of -0.84 provide insight into operational efficiency.
| Gross Margin | 56.16 |
| Operating Margin | -5.90 |
| Pretax Margin | -1.15 |
| Profit Margin | -0.84 |
| EBITDA Margin | -5.90 |
Scores
Panacea Biotec Limited posts an Altman Z-Score of 3.14, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.14 |